

EXHIBIT 13

Bringing together two leaders: AmpliSeq™ for Illumina

<https://www.youtube.com/watch?v=IWPaZX1TDa4>

January 8, 2018 - Illumina unexpectedly announces collaboration with Thermo Fisher with a joint product: “Ampliseq for Illumina”.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): January 8, 2018

Illumina, Inc.

(Exact name of registrant as specified in its charter)

But internal innovation is only part of the story. Our partnership strategy ensures that our customers will have access to best-in-class technology. With that in mind, I am very pleased to announce an exciting partnership with Thermo Fisher. This collaboration deeply integrates the leading and most trusted sequencers with the leading amplicon library prep technology. Thermo Fisher has 20 years of experience in PCR amplification chemistries that has enabled them to develop an amplicon library prep that is simple, fast and robust. The technology has been widely adopted in the oncology space because of the high-quality data achievable with low input and degraded samples, such as FFPE tissue.

But until now, those customers have not been able to take advantage of the accuracy and power of Illumina sequencers. This agreement provides direct access to AmpliSeq for our RUO customers, delivering the best of sequencing with the best amplicon protocol. Ahead of today's launch, we have been working together to adapt and optimize AmpliSeq specifically for Illumina sequencers, creating a seamless user experience that is fast and easy.

In addition to a collection of ready-to-order panels, Illumina customers will also be able to access AmpliSeq algorithms to create custom amplicon assays utilizing DesignStudio, our online assay design protocol, and they will have access to future panels and new assay types that are introduced as part of the AmpliSeq product line.

Amplicon sequencing is an important entry point for new NGS customers. The combination of our proven technologies further removes barriers to adoption, bringing more new-to-sequencing customers to our platform. Of course, we also have an installed base of more than 9,000 desktop systems. By giving our existing customers access to AmpliSeq chemistry, we're enabling them to do even more with their systems.

January 8, 2018 - Illumina CEO Francis deSouza admits secret collaboration with Thermo Fisher “started the conversation clearly well over a year ago” ... meaning prior to the settlement agreement.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): January 8, 2018

Illumina, Inc.

(Exact name of registrant as specified in its charter)

Tycho W. Peterson - JP Morgan Chase & Co, Research Division - Senior Analyst

Can you talk about just that Thermo agreement, how that came about? (inaudible) press releases in Illumina (inaudible), so just a bit of speculation on that part? I mean, what's the back story?

Francis A. deSouza - Illumina, Inc. - CEO, President & Director

So the question is about the partnership we have with Thermo and what's the back story or how did that come about. The way it came about is as we talk to our customers around what they are looking for, one of the things that we heard consistently is that they liked certain aspects of AmpliSeq. And so they would tell us, look, they love the low sample they put in AmpliSeq, for example. They like the ability to work with degraded samples like FFPE tissue, and AmpliSeq has a following in the oncology community in terms of people like that assay. And so we spent a lot of time internally thinking, look, we want to make sure our customers have the best experience in our sequencer. So what is great for our customers is ultimately good for Illumina.

And so we started the conversation clearly well over a year ago. And initially, it was one of those, like, "Are you sure -- are we sure we want to do this? Are they sure they want to do this?" But it was always -- so the true north for us was what's the best thing for our customers? And if you keep looking at that, the truth is the best thing for our customers is to make the best amplicon technology available on the best sequencer. And I think a lot of credit on both sides. Thermo had the same thinking, which is, yes, there are parts of our portfolio we compete, but this is clearly good for AmpliSeq, it's good for customers and it's good for us. And so that was the thinking behind it. I think we're out of time.

January 30, 2018 - Illumina highlights collaboration with Thermo Fisher joint product: “Ampliseq for Illumina” in SEC report.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 8-K

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 30, 2018

Illumina, Inc.

(Exact name of registrant as specified in its charter)

Updates since our last earnings release:

- Launched the iSeqTM 100 Sequencing System, a flexible benchtop sequencer priced at \$19,900 designed to provide a fast and easy-to-use system with unmatched accuracy
- **Announced availability of AmpliSeq for Illumina, developed in partnership with Thermo Fisher Scientific**
- Introduced the NextSeqTM 550Dx instrument, Illumina’s second FDA regulated CE-IVD market platform, to deliver the power of high-throughput next-generation sequencing (NGS) to the clinical laboratory



Bringing together two leaders: AmpliSeq™ for Illumina®
1,572 views 8 likes 0 dislikes SHARE

illumina Illumina Inc
Published on Jan 9, 2018 SUBSCRIBE 7.5K

1. I'm Joydeep Goswami, President of Clinical Oncology and NGS at Thermo Scientific



Bringing together two leaders: AmpliSeq™ for Illumina®
1,572 views 8 likes 0 dislikes SHARE

illumina Illumina Inc
Published on Jan 9, 2018 SUBSCRIBE 7.5K


2. My name is Mark Van Oene. I'm Illumina's Chief Commercial officer



Bringing together two leaders: AmpliSeq™ for Illumina®
1,572 views 8 likes 0 dislikes SHARE

illumina Illumina Inc
Published on Jan 9, 2018 SUBSCRIBE 7.5K

3. (Goswami, TMO) – Today I am really proud to be announcing a partnership with Illumina to bring the power of AmpliSeq library prep across all of Illumina's sequencing platforms...



Bringing together two leaders: AmpliSeq™ for Illumina®

1,572 views

8 0 SHARE

illumina

Illumina Inc
Published on Jan 9, 2018

SUBSCRIBE 7.5K

6. (Goswami, TMO) – Over several years customers on Illumina’s platforms have asked for AmpliSeq to be enabled on their instruments and part of that has been the ability of Ampliseq to be able to handle both DNA and RNA in a single workflow.

7. (Goswami, TMO) – To be able to handle complex FFPE samples especially where the quantity of DNA and RNA may be quite small.

4. (Oene, ILMN) – For both of us our customers are our number one priority. Our customers need that flexibility to choose the best solutions for their research. I’m really excited to bring AmpliSeq technologies for Illumina sequencers to market.

5. (Oene, ILMN) – This gives our customers access to the high value AmpliSeq chemistries. We’ve removed the barriers for them to integrate that with their existing technologies.



Bringing together two leaders: AmpliSeq™ for Illumina®


1,572 views

8 0 SHARE

illumina

Illumina Inc
Published on Jan 9, 2018

SUBSCRIBE 7.5K



Bringing together two leaders: AmpliSeq™ for Illumina®

1,572 views

8 0 SHARE


Illumina Illumina Inc
Published on Jan 9, 2018

SUBSCRIBE 7.5K

8. (Oene, ILMN) – We came together to create a seamless product and so Illumina next gen sequencing customers can order directly through Illumina now and know that we will have that seamless support from the Illumina organization as well...

9. (Oene, ILMN) – Customers regularly ask me if they can use this library prep approach on our sequencers. So I'm really excited to give them the flexibility to do this and add this to their workflows on their systems.

10. (Goswami, TMO) – We're really excited to be able to bring this jointly to our customers. This partnership will have a huge impact by enabling customers across multiple platforms use Ampliseq library prep to be able to conduct their experiments in NGS, but also then be able to more easily compare, share, and collaborate with those results and findings and insights across geographies and platforms.




Bringing together two leaders: AmpliSeq™ for Illumina®

1,572 views

8 0 SHARE

Illumina Illumina Inc
Published on Jan 9, 2018

SUBSCRIBE 7.5K



11. (Oene, ILMN) – We have a wide variety of tools that exist today but customers continue to ask about AmpliSeq and they love the simplicity of this and the performance characteristics of it.

12. (Oene, ILMN) – So really excited to add this to our portfolio of products for them to drive the innovation and understanding of genetics.

Bringing together two leaders: AmpliSeq™ for Illumina®


1,572 views

👍 8 🗨️ 0 ➦ SHARE ⋮ ...

illumina **Illumina Inc**
Published on Jan 9, 2018

SUBSCRIBE 7.5K

Learn more about AmpliSeq™ technology



Bringing together two leaders: AmpliSeq™ for Illumina®

1,572 views

👍 8 🗨️ 0 ➦ SHARE ⋮ ...

illumina **Illumina Inc**
Published on Jan 9, 2018

SUBSCRIBE 7.5K